<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.2217/nnm-2019-0371</dc:identifier><dc:language>eng</dc:language><dc:creator>Lacoma, Alicia</dc:creator><dc:creator>Usón, Laura</dc:creator><dc:creator>Mendoza, Gracia</dc:creator><dc:creator>Sebastián, Víctor</dc:creator><dc:creator>Garcia-Garcia, Esther</dc:creator><dc:creator>Muriel-Moreno, Beatriz</dc:creator><dc:creator>Domínguez, José</dc:creator><dc:creator>Arruebo, Manuel</dc:creator><dc:creator>Prat, Cristina</dc:creator><dc:title>Novel intracellular antibiotic delivery system against Staphylococcus aureus: Cloxacillin-loaded poly(d, l-lactide-co-glycolide) acid nanoparticles</dc:title><dc:identifier>ART-2020-118681</dc:identifier><dc:description>Aim: First, to compare in vitro minimum inhibitory concentrations (MIC) of free cloxacillin and cloxacillin-containing nanoparticles (NP) against methicillin-susceptible (MSSA) and resistant Staphylococcus aureus (MRSA) and second, to assess NP antimicrobial activity against intracellular S. aureus. Methods: Poly(d, l-lactide-co-glycolide) acid (PLGA)-NP were loaded with cloxacillin and physico-chemically characterized. MICs were determined for reference strains Newman-(MSSA) and USA300-(MRSA). Murine alveolar macrophages were infected, and bacterial intracellular survival was assessed after incubating with free-cloxacillin or PLGA-cloxacillin-NP. Results &amp; conclusion: For both isolates, MICs for antibiotic-loaded-NP were lower than those obtained with free cloxacillin, indicating that the drug encapsulation improves antimicrobial activity. A sustained antibiotic release was demonstrated when using the PLGA-cloxacillin-NP. When considering the lowest concentrations, the use of drug-loaded NP enabled a higher reduction of intracellular bacterial load.</dc:description><dc:date>2020</dc:date><dc:source>http://zaguan.unizar.es/record/156575</dc:source><dc:doi>10.2217/nnm-2019-0371</dc:doi><dc:identifier>http://zaguan.unizar.es/record/156575</dc:identifier><dc:identifier>oai:zaguan.unizar.es:156575</dc:identifier><dc:relation>info:eu-repo/grantAgreement/EUR/ERC-2013-CoG-614715-NANOHEDONISM</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/FEDER/PI17-01139</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/CTQ2017-84473-R</dc:relation><dc:identifier.citation>Nanomedicine 15, 12 (2020), 1189-1203</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>https://creativecommons.org/licenses/by/4.0/deed.es</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>